T.P.3.02 Use of glucocorticoids in Duchenne MD: Consensus report of the CDC Duchenne care considerations neurology panel
Richard S. Finkel(St. Jude Children's Research Hospital), K. Bushby(Newcastle University), Diana M. Escolar(Children's National), Brenda Wong(Cincinnati Children's Hospital Medical Center), Carsten G. Bönnemann(National Institute of Neurological Disorders and Stroke), Carolyn M. Constantin(Centers for Disease Control and Prevention), E W Massey(Duke University), Doug Biggar(Holland Bloorview Kids Rehabilitation Hospital), J. Pascual(The University of Texas Southwestern Medical Center), John T. Sladky(Emory University), Kathryn R. Wagner(Kennedy Krieger Institute), Timothy M. Miller(Valve (United States))
Cited by 0
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Improving genetic diagnosis in Mendelian disease with transcriptome sequencing
|Science Translational Medicine|2017|809
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565